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Which should be the first-line treatment for Helicobacter pylori in 
Colombia? A lesson from a recent study
Turin, August 30th, 2019
Dear Editor, 
In the last decades, the recommended regimens for Helicobacter pylori 
eradication have included the combination of a proton-pump inhibitor (PPI) 
and two or more antibiotics (1). Among the latter, clarithromycin is widely used 
to treat H. pylori infection, due to its low minimal inhibitory concentration. 
However, due to a steady increase in H. pylori resistance to clarithromycin, 
this drug has become progressively less efficacious worldwide. 
To highlight the concerns caused by the increasing resistance of this 
bacterium to antibiotics, the World Health Organization inserted H. pylori with 
high priority for clarithromycin resistance, in the priority list for research and 
development of new antibiotics (2). A European multicentre study, published 
in 2013, showed that the resistance rate of H. pylori in Europe was 34.9% 
for metronidazole, 17.5% for clarithromycin, 14.1% for levofloxacin, 1.1% for 
rifabutin, 0.9% for tetracycline, and 0.7% for amoxicillin (3). 
The dominant mechanisms underlying the development of clarithromycin 
resistance are several point mutations in domain V of the 23S ribosomal 
RNA (rRNA) gene, which result in decreased affinity and in absence of 
clarithromycin binding to the 50s ribosome subunit, and thus, failure to 
influence protein synthesis. 
It is well-known that clarithromycin resistance may originate from the previous 
consumption of macrolides. There are essential point mutations, which 
can occur at the nucleotide positions 2142 (A2142G and A2142C), 2143 
(A2143G) and 2144 (A2144G) in the peptidyl transferase loop of the 23S 
rRNA gene. These mutations result in conformational change leading to 
decreased efficacy of the drug (4).
In a recent interesting article, Roldán, et al., reported the frequency of 
A2143G and A2142G mutations in patients with previous unknown H. pylori 
status, admitted for dyspepsia in an endoscopic unit in Medellín, Colombia. 
They found a prevalence of 44.2% of H. pylori infection with A2143G 
and A2142G mutations in the 18.8% of them (5). These results must be 
considered together with the data regarding the high rate (78%) of RdxA 
nitroreductase mutations (associated with metronidazole resistance) shown in 
H. pylori strains in Colombia (6). 
Considering that beyond its involvement in several gastro-duodenal diseases, 
H. pylori is recognized as a necessary but insufficient cause of gastric cancer, 
it is possible that eradication at a population level may lead to the future 
decline of this malignancy, especially in countries where it represents a 
severe burden. Hence, it is crucial to optimize the treatment in each country. 
These findings indicate that also in Colombia should be appropriate to treat 
patients with new therapeutic options, in particular the formulation with 
bismuth subcitrate potassium, metronidazole, and tetracycline contained in a 
single capsule (three-in-one). Due to its efficacy the International Guidelines 
recommended this regimen as first line and second line therapies in regions 
where clarithromycin resistance has resulted in low-cure rates (7).
Cartas al editor
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Very truly yours, 
Rinaldo Pellicano
Unit of Gastroenterology, Molinette-SGAS Hospitals, Via Cavour 31, 10126 
Turin, Turin 10123, Italy
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Medellín, October 31st., 2019
Dear Dr. Pellicano, 
We would like to thank you for your interest and comments about our 
manuscript, which we found extremely useful (1). Since Colombia is a country 
with a high gastric cancer incidence we agree with your observation: “The 
Helicobacter Pylori eradication could lower the morbidity rate for this cancer.  
However, this rate diminution has been shown to have a dramatic downward 
trend because of the antibiotic resistance” (2). Therefore, we must implement 
optimal eradication regimens according to the pertinent antibiotics. 
Worldwide (with rare exceptions) the use of clarithromycin regimens are 
no longer appropriate because of the low eradication rates (<80%) (3,4). 
Even more concerning, the alternative levofloxacin therapies (quadruple, 
sequential, concomitant and triple therapies) efficacy has decreased (5,6). 
While the resistance increases, the standard triple therapy success has 
decreased below 60% (2,7–11), The H. pylori empirical treatment has 
contributed to the misuse of antibiotics. Although the latest international 
consensus reports suggest selection of treatment according to local 
resistance patterns (12–20) H. pylori sensitivity test is rarely performed. 
The standard triple therapy is no longer use in Europe, and the quadruple therapy 
is now used instead (12). Nevertheless, since there is not consensus with this 
treatment a random combination is used worldwide, especially in regions with high 
resistance rates leading to the increase of quinolones and rifabutin resistance (21).
Unfortunately, in our experience most of the patients with failure treatment 
have shown multiple concurrent clarithromycin and metronidazole 
resistance, or even a triple resistance to clarithromycin, metronidazole, and 
fluoroquinolone (according to the culture susceptibility test) (7). As a result of 
antibiotics misuse, concomitant quadruple therapy is rapidly losing its efficacy. 
Since 2015, Kioto´s H. pylori consensus defined it as an infectious disease 
regardless of the symptoms and complications (22). Maastricht´s V 
Consensus recommended that after the second-line treatment failure, H. 
pylori treatment should be guided according to the sensitivity tests (12). If the 
correct antibiotics are chosen for the first therapy the success rate is higher, 
while after first therapy failure the bacteria will probably develop antibiotic 
resistance and it would be harder to eliminate. 
Bismuth is a medicament very effective to treat H. pylori infection and most of 
the consensuses recommend it because resistance against it has not been 
described yet (12,15,19,20). However, since bismuth is not absorbed it is not 
effective against intracellular and pericellular bacteria. Therefore, bismuth 
should be used in combination with additional medicaments to successfully 
eradicate the infection. Dore, et al., demonstrated that adding bismuth to the 
triple therapy could increase the curation rate against resistant strains, but 
bismuth is rarely added to the first-line H. pylori triple treatment (23). 
In our practice, as second-line therapy and increasingly more frequent as 
first-line therapy, the proton pump inhibitors (PPI), amoxicillin, levofloxacin 
and bismuth combined treatment achieve over 90% success rates in clinical 
trials performed since 2010 (24). We are currently working on a project trying 
this therapy with our patients because H. pylori will not become resistant to 
bismuth and it could prevent Clostridium difficile complications. 
Besides choosing the correct antibiotics according to the sensitivity tests, 
the acid gastric inhibition plays a key role in treatment success. Therefore, 
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choosing the correct PPI with the higher effectiveness over the acid and a 
lower influence for the host´s CYP2C19 polymorphisms (rabeprazole and 
esomeprazole) could improve the cure rate (21). Maastricht´s V Consensus 
establishes that a high PPI dose controls better the gastric pH, thus 
increasing the therapy efficacy (12). Since the acid inhibition power differs in 
different PPI, duplicating the standard dose of any of these PPI would provide 
a better outcome (25).
As a summary, H. pylori is an infectious disease and its eradication can be 
achieved (≥95% cure rate) with well-designed therapies based not only in 
antibiotic selection (precise selection) according to the antimicrobial sensitivity 
tests and cultures, but also with the patient´s adherence to the treatment 
and the correct PPI dose. Due to the high resistance, gastroenterologists 
must handle it as an infectious disease and change the empirical treatment 
model for a precision therapy guided by antimicrobial susceptibility tests. The 
treatment program needs to be applied in the local, regional and national 
environment to track the H. Pylori resistance patterns to antibiotics.
Sincerely yours,
Ingrid Johana Roldán, Rodrigo Castaño, María Cristina Navas
Grupo de Gastrohepatología, Facultad de Medicina, Universidad de 
Antioquia, Medellín, Colombia
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